Cantor Fitzgerald Reaffirms Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports.

A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Monday. Roth Mkm raised their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Maxim Group boosted their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Canaccord Genuity Group cut their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, September 18th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $7.12 on Tuesday. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95. The company has a market capitalization of $297.99 million, a price-to-earnings ratio of -5.27 and a beta of 1.94. The company has a 50-day simple moving average of $7.18 and a 200 day simple moving average of $5.77. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same quarter in the prior year, the firm earned ($0.15) EPS. On average, sell-side analysts predict that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director Thomas Anderson purchased 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The shares were acquired at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $136,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought a total of 22,000 shares of company stock valued at $140,340 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after buying an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its holdings in shares of Zevra Therapeutics by 6.5% in the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock worth $2,246,000 after acquiring an additional 28,107 shares during the last quarter. Mystic Asset Management Inc. boosted its stake in shares of Zevra Therapeutics by 11.9% in the 2nd quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock valued at $1,460,000 after purchasing an additional 31,650 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of Zevra Therapeutics during the 4th quarter valued at approximately $1,755,000. Finally, Bank of New York Mellon Corp increased its position in Zevra Therapeutics by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after purchasing an additional 21,231 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.